Belite Bio Seeks Japan Drug Approval for Tinlarebant Stargardt

Belite Bio submitted a New Drug Application to Japan's Ministry of Health, Labour, and Welfare for its investigational oral therapy tinlarebant, aiming to treat Stargardt disease type 1 under the expedited Sakigake designation system.

"The NDA submission in Japan under Sakigake designation reflects the significant unmet need for people living with STGD1 and is backed by our robust data showing tinlarebant’s ability to slow the growth rate of retinal lesions compared to placebo. This is another important milestone as we continue to make rapid progress against our goal to bring tinlarebant to STGD1 patients around the world," said Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio.

Clinical Need and Market Impact in Japan

Stargardt disease type 1 affects approximately 9,500 individuals in Japan, representing a significant patient population with no currently approved treatments. Although the inherited retinal dystrophy was first documented nearly 120 years ago, therapeutic options have remained nonexistent.

"Although Stargardt disease was first described nearly 120 years ago, no approved treatment has been established to date. We view our NDA in Japan as an important step toward delivering the first therapeutic option in the country for people living with Stargardt disease," said Kaz Tsunaba, President of Belite Bio Japan, in a statement.

If the application secures approval through the Sakigake designation pathway, which aims to promote breakthrough therapies originating in Japan, tinlarebant would become the first approved treatment for Stargardt disease type 1 globally. It could also mark the first Sakigake-designated pharmaceutical product for an ophthalmology indication in the country.

Parallel Regulatory Milestones in the United States

The Japanese submission coincides with parallel regulatory progress in the United States. Belite Bio filed its New Drug Application side-by-side with U.S. regulators, where the U.S. Food and Drug Administration accepted the filing for Priority Review. U.S. health authorities have set a Prescription Drug User Fee Act target action date of February 12, 2027.

Clinical data supporting both filings demonstrated that tinlarebant successfully slowed the growth rate of retinal lesions compared to a placebo group. The oral therapy is designed to reduce the accumulation of toxic vitamin A dimers in the retina, which drive cell death and progressive vision loss in Stargardt patients.